BioNTech SE
BioNTech SE
About

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. Its cutting-edge pipeline includes individualized mRNA-based product candidates, innovative chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies and small molecules. BioNTech’s product development approach has been validated by seven collaborations with, in chronological order, Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and its scientific approach through over 150 peer-reviewed scientific publications. BioNTech’s shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices.

Read more

Type of organization

1 office
2008
Similar organizations
European Medicines Agency (EMA)
European Medicines Agency (EMA)
GovernmentService Providers
4 open positions
UN Technology Bank for the Least Developed Countries
2 open positions
Youth Challenge International (YCI)
Youth Challenge International (YCI)
Implementing NGOService Providers
1 open position

Company Offices

  • Germany
  • Mainz
  • An der Goldgrube 12